Eli Lilly and Co. (LLY) has unveiled detailed results from the QWINT-2 phase 3 trial, which assessed the efficacy of once-weekly insulin efsitora alfa (efsitora) against the once-daily insulin degludec. This study focused on adults with type 2 diabetes who are initiating insulin therapy (insulin naive).The trial demonstrated that efsitora successfully met the primary endpoint of non-inferior A1C reduction. Specifically, efsitora reduced A1C levels by 1.34%, compared to a 1.26% reduction with insulin degludec, resulting in final A1C levels of 6.87% and 6.95%, respectively, over 52 weeks.Additionally, those using efsitora achieved an extra 45 minutes of time within the desired glucose range per day compared to participants using insulin degludec, a key secondary endpoint. Importantly, this improvement did not come with an increased duration of hypoglycemia (glucose levels below 54 mg/dL).In terms of safety, efsitora showed a comparable profile to daily insulins. Notably, there were no severe hypoglycemic events reported with efsitora, while six such events were observed with insulin degludec. The overall incidence of hypoglycemia was low, with combined rates of severe or clinically significant hypoglycemic episodes per patient-year of exposure standing at 0.58 for efsitora versus 0.45 for insulin degludec.Furthermore, the study highlighted that the estimated combined rates of severe or clinically significant nocturnal hypoglycemic events per patient-year of exposure were identical at 0.08 for both efsitora and insulin degludec. Hypoglycemia rates were consistent across participants, regardless of GLP-1 usage. Adverse event rates were also similar between the two treatment groups.The material has been provided by InstaForex Company – www.instaforex.com
- Oracle To Invest More Than $6.5 Bln In Malaysia For AI And Cloud Services - October 2, 2024
- Romania’s Producer Price Index Sees Slight Uptick in August 2024 - October 2, 2024
- Kenya’s GDP Growth Slows to 3.60% in Q2 2024 Amid Economic Headwinds - October 2, 2024
